Syncona Investee Achilles Reports Positive Trial Review, Mulling IPO
Syncona Investee Achilles Reports Positive Trial Review, Mulling IPO
Read moreTo deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.
Find out MoreWed, 06th Jan 2021 08:36
Syncona Investee Achilles Reports Positive Trial Review, Mulling IPO
Read more(Sharecast News) - Healthcare investor Syncona said on Friday that its portfolio company Achilles Therapeutics, which is developing precision T-cell therapies to treat solid tumours, had announced that an independent data and safety monitoring committee had completed the first review of the ongoing, first-in-human phase 1 and 2 'CHIRON' and 'THETIS' trials.
Read moreSyncona Investee Autolus To Focus On Adult Leukemia Programme in 2021
Read moreUK EXECUTIVE CHANGE SUMMARY: Ferguson Taps Former Ashtead, Bunzl Execs
Read moreSyncona Portfolio Companies Boost Interim Result; Launches New Company
Read more(Sharecast News) - Healthcare company Syncona reported a "robust" performance for the six months up to 30 September in which its net assets reached a value of £1,366.7m at 203,4p per share and a net asset value total return of 9.6% in the period.
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreUK EXECUTIVE CHANGE SUMMARY: Kakuzi Acts To Prevent Human Rights Abuse
Read moreSyncona Investee Freeline Posts Widened Interim Loss On Higher Costs
Read more(Sharecast News) - Healthcare investment firm Syncona said on Friday that portfolio business Freeline Therapeutics had seen interim losses widen as a result of increased research and development costs.
Read moreUK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation
Read moreSyncona Life Science Portfolio Boosted By Autolus And Freeline
Read moreSyncona Investee Freeline Therapeutics Prices IPO In New York
Read more(Sharecast News) - Healthcare investment company Syncona announced on Friday that its portfolio company Freeline Therapeutics has priced its initial public offering in the United States.
Read more